Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool ; volume:8 ; number:1 ; day:9 ; month:10 ; year:2013 ; pages:1-5 ; date:12.2013
Orphanet journal of rare diseases ; 8, Heft 1 (9.10.2013), 1-5, 12.2013
- Urheber
-
Picavet, Eline
- Beteiligte Personen und Organisationen
-
Cassiman, David
Aertgeerts, Bert
Simoens, Steven
SpringerLink (Online service)
- DOI
-
10.1186/1750-1172-8-157
- URN
-
urn:nbn:de:1111-2016050123907
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Picavet, Eline
- Cassiman, David
- Aertgeerts, Bert
- Simoens, Steven
- SpringerLink (Online service)
Ähnliche Objekte (12)
The European challenges of funding orphan medicinal products
Comparing access to orphan medicinal products in Europe
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
Natural products in medicinal chemistry
10th European Conference on Rare Diseases & Orphan Products (ECRD 2020)
The European challenges of funding orphan medicinal products
Comparing access to orphan medicinal products in Europe
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
Natural products in medicinal chemistry
10th European Conference on Rare Diseases & Orphan Products (ECRD 2020)
The European challenges of funding orphan medicinal products
Comparing access to orphan medicinal products in Europe
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
Natural products in medicinal chemistry